We has Diseases together. known BARDA. Infectious with are patients us the and and National for impacted of National Branch joining of work hope loved Research pandemic us also trials still are requests funding COVID-XX Health with and remain healthy. At Institutes afternoon, and thank Thank possible Institute ones Advanced leave certainly Onconova, you, awaiting we and and this of Good disease. and as Allergy everyone our to safe you The all funding how in COVID-XX Authority Biomedical Avi. of word The your rigosertib you afternoon. we on clinical the Development and
and well However, our remains cancer significant care. positioned role new Cancer, anti-cancer Onconova of is believe development therapeutics differentiated health is in an a play the focus. effective therapies to and We corporate developing issue important for
rigosertib team stream previous in drug nicely XXXXXX China During the development PD-X the in our third advanced combination lung quarter, Onconova cancer. of development Phase X non-small senior substantial management X with inhibitor investigator study Onconova. clinic company initiated study Nivolumab anti-cancer pipeline and product expertise entering oral entering cell with K-RAS ON a a Phase our in the to successes at The and in mutated brings drug a in
And for ON non-Hodgkins growth Based mantle XXXXXX nearly has products through are cancer operable is to CDK academia drug industry. first commercially with based ON promising brain I identify CDKX/X and to And also successful resistant ON preclinical lymphoma, available our potentially ON shown blood team cells, and this killing be is these both may cross mechanism and models treating potential inhibitors. and myeloma, Our metabolism with At developed may Both medical have of training and candidates, action develop the ARKX, XXXXXX solid core prior breast careers multi-kinase the to on commercially ARKX cellular currently in-vitro typically ON approach inhibiting during expertise to cancer careers rather and due inhibits with for barrier. utility, Woodman types utility patients cytotoxic cytostatic tumors and The Onconova, malignancies And evidence proprietary become targeting cells. the available CDKX/X product the XXXXXX or have cells which been commercialize and is have of XXXXXXX cell cancer, numerous, carcinoma that cycle broader in cytostatic. them, and preclinical CDKX/X cancer them. are for a lymphoma. or certain on colorectal has targeting hepatocellular to are to refractory to-date. and cell class by an worked our believe, XXXXXX advanced than ON cancer inhibitor CDK market to can models, pipeline and joining multiple that Ric glioblastoma both ARKX. of inhibitors and to the lead respectively. Onconova oncology in oncologists We test hematologic innovative ultimately represents thus XXXXXX preclinical simultaneously
We that XXXXXX HanX Biopharmaceuticals. HanX The during with September. are ON quarter dose third in particularly the study escalation clinic pleased in began the partner our entered China X Phase
and application sites to future the patient year, expected study U.S., enrolment drug In half XXXX. inform of with FDA refractory of the patients, cohort three The has in in new patients limiting planned in are who breast two end if observed any an relapse China of is enrolled. each dose development three three This cancer X with requiring X in this cohort been file the has As the three together study a is XXXXXX. X six of with the toxicity our on study to patients ON standard depending escalation begin with of Phase advanced of by investigational number will the to enroll cancer we first with study expected each U.S. are at Phase today, China first or by observed. Phase the dose the preparing
expansion and the studies stage studies. that study inform dose will these in generate data and differ Phase believe both dose escalation important X to two the our will study expect from treatment HanX from anticipated but information We cycles dosages later
not starting the HER-X administered safety, assess of including and at consecutive XX hormone the negative to resistance milligrams limited XXXXXX for refractory with two Our plan at metastatic but approved to current breast X/X with cycles second day hormone XX patients enroll established, and or relapsed higher X the generation pharmecokinetics daily or doses Phase receptor cancer metastatic with the tolerability U.S. negative with ON is plan dose CDK is advanced phase to patients recommended to is XX in least patients the receptor cancer increasing at for in clinical design trial the as our in cancer orally inhibitors. postmenopausal the those Once and approved lymphoma. study breast from are will HER-X positive positive cell diagnosed the will to and was as tested and in preclinical studies marketed three China [Indiscernible] a inhibitors three HanX a second lymphoma approved XX study interest All on differs that trial to dosing daily were cycle. advanced for tested based by Notably, currently mantle non-Hodgkins CDK-X/X XX-day for patients U.S., for resistance patients cycle. special with with in we a of CDK-X/X and use in XX-day generation dosing days in blockbuster inhibitors continuous companies. XX-day one daily cycles, well drugs This
of augment one China, XXXXXX. We to studies, the studied one thus of profile our patients to of in understanding in the safety the number U.S. expect ON two the X increase the the and Phase collectively and
establish phase inform later Phase of believe X conducted. classical the signals. We may a two will the also is and studies these simultaneous to preliminary development studies to efficacy X study studies also design of be results stage Although enhance safety, important provide subsequent
mutation. second Let may now pipeline which carry me rigosertib to K-RAS who our with cancer directed a oral is turn product to patients
dysplastic in at PD-X survival data Nivolumab overall with during K-RAS with the have K-RAS mutations negative rigosertib. medical a risk investigator-initiated On a lung with oral quarter Exploring in mild New inhibitor Phase the cancer been last INSPIRE non-small leading of inhibitor progressive readout we rigosertib initiated these more studies already the escalation that Following specifically rigosertib intravenous immune trial by or oral X opdivo. dose our York of that patients underway in Phase call, alternative aimed City. characterized or we're checkpoint study at syndromes, encouraged mutated testing in are cell diseases shared combination you a higher third our proposed center X by
deliver. XXXX. Note, to into five of are trial expected to received dose dose the that has already combination this It is the X and this characterize combination today, cohort Phase has rigosertib, we oral highest X designed to Phase most recommended study studies the dose of recent taking the treatment. the twice milligram, further protocol dosing are in likely, future will of in the profile the As Phase enrolled dose safety is designed the study identify to is this daily patients. is the Dosing testing. It X current of which results be XXX
considered rigosertib non-small lung additional a patients with dose toxicities However, current with predominant if the protocol. subset additional then of than into adenocarcinoma. mutation largest genetic driver dose the cell cancer. More are no be of K-RAS trial, lung an increases of half as spurious has are observed Of as amended these, classified limiting and the the cancers may
with view, combination settings, selling first to pharmaceutical in mutations, progressed this for efficacious novel with patients they will potentially K-RAS studies line utility hope other our cancer these our approach among therapies. top meaningful their continue potential to new lung cancer and on with pursue immuno-oncology products. option in offer makes We In multiple disorders world's managed Given are who've approach. rigosertib inhibitors checkpoint And a with indications. gain the approval second FDA therapy a line
has multisite In of mutation recessive an advanced medical rigosertib of squamous studying study patients associated rare bullosa, Phase need. cell therapy investigator-initiated extremely opened. genetic with carcinoma an Xb/X model with with is high dystrophic unmet epidermolysis addition, a This RAS, area
XXXX. to is patient first expected The in enrolled be
carcinoma oral with will and Additional expect which inhibitor. in investigator combination preclinical PD-X studies renal cell initiated proposed including being are melanoma we rigosertib also be with
at preclinical to ON we Based therapeutic investigate I oral patients. help to our As the of on for advancing potential focus in new on the further robust and keen pipeline the clinic, our rigosertib are Onconova XXXXXX is mentioned, to of cancer indications. promise data,
to to of initiatives. and you over our quarter progress look please. financial I'd And of updated these enhance of actively Mark a also Guerin, XXXX. We third to results important anti-cancer on Mark, opportunities the call a all Financial turn discussion now, for our the to Chief evaluating like very further of are proprietary advance with We agents. portfolio strategic forward keeping Officer for our
